Track topics on Twitter Track topics that are important to you
Global Smart Inhalers Market to reach USD 829.3 Million by 2025.
Global smart inhalers market is valued at approximately USD 16.4 Million in 2017 and is anticipated to grow with a healthy growth rate of more than 63.3 % over the forecast period 20182025. Technological advancements in smart inhalers is the major trend that are responsible for the wide adoption of smart inhalers globally.
Global smart inhalers market is mainly driven by rising prevalence of respiratory diseases such as asthma and COPD. According to WHO, over 90 % of COPD Chronic obstructive pulmonary disease observed in middle lowincome countries. The prevalence of COPD and asthma is rising due to several reasons such as growing consumption of tobacco and cigarettes, rising aging population and growth of air pollutants. The prevalence rate of COPD is high in the United States. COPD is the third leading cause of death in the United States. Further, according to the Asthma Organization UK, in 2015 around 5.4 million people in United Kingdom are presently receiving asthma treatment out of which 4.3 million are adults and rest 1.1 million are children. Moreover, in United Kingdom one in every 11 people is suffering from asthma. This clearly states that there is high prevalence of respiratory diseases positively affects the demand for the smart inhalers. However, lower acceptance in emerging economies is the major factor that impede the growth of global smart inhalers market.
On the basis of segmentation, the smart inhalers market is segmented into product, indication and enduser. The product segment of global smart inhalers market is classified into inhalers and nebulizers of which inhalers dominates the major as inhalers are preferred as first option of treatment, portability. Based on indication, the smart inhalers market is classified into asthma and COPD. On the basis of enduser, the market is classified into patients and research development.
The regional analysis of smart inhalers market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America have occupied major share in the global smart inhalers market. The major reasons for the dominance of North America are high awareness regarding asthma and COPD treatment, high technological innovations in healthcare sector, high adoption of smart inhaler device and growing adoption of IOT in healthcare industry. Whereas, AsiaPacific is expected to emerge as the fastest growing region in terms of market share. The growth of AsiaPacific region is witnessed owing to growing population affected with respiratory diseases due to rising air pollution.
The leading market players mainly include
Teva Pharmaceuticals Industries Ltd
Vectura Group PLC
Boehringer Ingelheim Gmbh
Cohero Health LLC
Glaxo SmithKine PLC
The objective of the study is to define market sizes of different segments countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and subsegment of the market are explained below:
oMetered Dose Inhalers
oDry powder inhalers
oMiddle East Africa
Furthermore, years considered for the study are as follows:
Historical year 2015, 2016
Base year 2017
Forecast period 2018 to 2025
Target Audience of the Global Smart Inhalers Market in Market Study:
Key Consulting Companies Advisors
Large, mediumsized, and small enterprises
ValueAdded Resellers VARs
Thirdparty knowledge providers
Original Article: Global Smart Inhalers Market Size study, by product inhalers and nebulizers, Indication COPD and asthma, Enduser patients and RD and Regional Forecasts 20182025. [Report Updated: 14022019] Prices from USD $3950NEXT ARTICLE
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal. When you come into contact with something that irritates your...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...